Newnorm

BIOLOGICAL2 trials

Sponsors

Octapharma Pharmazeutika Produktionsgesellschaft mbH, Octapharma

Conditions

Human Normal ImmunoglobulinPrimary Immune Deficiency

Phase 3

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Active, not recruitingNCT04640142

OctapharmaPrimary Immune Deficiency

Start: 2021-08-04End: 2026-09-01Updated: 2026-08-06

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

Active, not recruitingCTIS2024-511231-94-00

Octapharma Pharmazeutika Produktionsgesellschaft mbHHuman Normal Immunoglobulin

Start: 2021-10-27Target: 50Updated: 2025-10-14